^
    7d
    BGB-B2033-101: A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Selected Advanced or Metastatic Solid Tumors (2025-524136-19-00)
    P1, N=56, Not yet recruiting, BeOne Medicines AG
    New P1 trial
    |
    Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr)
    9d
    Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC (clinicaltrials.gov)
    P1/2, N=590, Recruiting, RayzeBio, Inc. | Phase classification: P1 --> P1/2 | N=70 --> 590 | Trial completion date: Jan 2031 --> Jun 2031 | Trial primary completion date: Mar 2029 --> Jun 2030
    Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    19d
    BANTAM-01: A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer (clinicaltrials.gov)
    P1, N=148, Recruiting, Bayer | Trial completion date: Dec 2033 --> Aug 2031 | Trial primary completion date: Jul 2030 --> Jul 2029
    Trial completion date • Trial primary completion date • First-in-human
    |
    GPC3 (Glypican 3)
    2ms
    A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment (clinicaltrials.gov)
    P1, N=50, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    GPC3 (Glypican 3)
    |
    codrituzumab (RG7686)
    3ms
    Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=33, Terminated, Sanofi | Active, not recruiting --> Terminated; Early discontinuation based on strategic sponsor decision not driven by any safety concerns
    Trial termination • First-in-human
    |
    ALK (Anaplastic lymphoma kinase) • GPC3 (Glypican 3)
    |
    Tecentriq (atezolizumab) • SAR444200
    4ms
    NWRD06 DNA Plasmid for HCC After Curative Resection. (clinicaltrials.gov)
    P2, N=30, Recruiting, Newish Technology (Beijing) Co., Ltd.
    New P2 trial
    |
    GPC3 (Glypican 3)
    4ms
    BANTAM-01: A Multicenter, Open-Label, First-in-Human Phase 1 Dose Escalation and Expansion Study of 225Ac-GPC3 (BAY 3547926) in Patients with Advanced Hepatocellular Carcinoma. (PubMed, J Nucl Med)
    Study recruitment commenced in March 2025, and approximately 148 participants will be enrolled. The study will provide important preliminary insights on the efficacy and safety of 225Ac-GPC3 ACC therapy.
    P1 data • Journal • First-in-human
    |
    GPC3 (Glypican 3)
    4ms
    MTX-GPC3-303: A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC (clinicaltrials.gov)
    P1, N=70, Recruiting, Myeloid Therapeutics | N=48 --> 70 | Trial completion date: May 2026 --> May 2028 | Trial primary completion date: Jul 2025 --> Dec 2027
    Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    4ms
    Organ-specific delivery of an mRNA-encoded bispecific T cell engager targeting glypican-3 in hepatocellular carcinoma. (PubMed, Nat Commun)
    No severe adverse effects or gross pathology were observed. Our results thus support the advancement of MTS105 into clinical trials, with a first-in-human study currently underway.
    Journal
    |
    CD8 (cluster of differentiation 8) • GPC3 (Glypican 3)
    4ms
    A Study of JMT106 Injection in the Treatment of Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=200, Recruiting, Shanghai JMT-Bio Inc.
    New P1 trial
    5ms
    ARYA3: T-Cell Therapy (ECT204) in Adults With Advanced HCC (clinicaltrials.gov)
    P1/2, N=20, Recruiting, Eureka Therapeutics Inc. | Phase classification: P2 --> P1/2
    Phase classification
    |
    GPC3 (Glypican 3)
    |
    cyclophosphamide • ECT204
    7ms
    Identification and non-clinical characterization of SAR444200, a novel anti-GPC3 NANOBODY® T-cell engager, for the treatment of GPC3+ solid tumors. (PubMed, Mol Cancer Ther)
    The highly potent and efficacious activity of SAR444200 in diverse models of GPC3+ tumors and the extremely wide tolerated dose range merits further development of this compound. Furthermore, NANOBODY®-based TCEs developed using an anti-TCRαβ moiety may have specific advantages for the development of TCEs.
    Journal • IO biomarker
    |
    GPC3 (Glypican 3) • CD3E (CD3 Epsilon Subunit Of T-Cell Receptor Complex)
    |
    SAR444200